The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation

American Journal of Transplantation

Volumn 11, Issue 3, 2011, Pages 500-510

  Musat, Alexandru I ^a   Agni, R M ^a   Wai, P Y ^a   Pirsch, J D ^a   Lorentzen, D F ^a   Powell, A ^a   Leverson, G E ^a   Bellingham, J M ^a   Fernandez, L A ^a   Foley, D P ^a   Mezrich, J D ^a   D'Alessandro, A M ^a   Lucey, M R ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Complement C4d; HLA antibodies; Liver transplantation; Rejection

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; COMPLEMENT COMPONENT C4D; CYCLOSPORIN A; DEXAMETHASONE; DONOR SPECIFIC HLA ALLOANTIBODY; HLA ANTIBODY; IMMUNOGLOBULIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; CHOLESTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; DUCTOPENIA REJECTION; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; SPLENECTOMY;

EID: 79951976611     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03414.x     Document Type: Article

References (57)

1. Turgeon NA, Kirk AD, Iwakoshi NN. Differential effects of donor-specific alloantibody. Transplant Rev (Orlando) 2009; 23: 25-33.
2. Montgomery RA, Hardy MA, Jordan SC et al. Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols. Transplantation 2004; 78: 181-185.
3. Pascual J, Samaniego MD, Torrealba JR et al. Antibody-mediated rejection of the kidney after simultaneous pancreas-kidney transplantation. J Am Soc Nephrol 2008; 19: 812-824.
4. Sis B,Mengel M, HaasMet al. Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464-471.
5. Kfoury AG, Renlund DG, Snow GL et al. A clinical correlation study of severity of antibody-mediated rejection and cardiovascular mortality in heart transplantation. J Heart Lung Transplant 2009; 28: 51-57.
6. Torrealba JR, Samaniego M, Pascual J et al. C4d-positive interacinar capillaries correlates with donor-specific antibody-mediated rejection in pancreas allografts. Transplantation 2008; 86: 1849-1856.
7. Morrell MR, Patterson GA, Trulock EP, Hachem RR. Acute antibody-mediated rejection after lung transplantation. J Heart Lung Transplant 2009; 28: 96-100.
8. Knechtle SJ, Kolbeck PC, Tsuchimoto S, Coundouriotis A, Sanfilippo F, Bollinger RR. Hepatic transplantation into sensitized recipients. Demonstration of hyperacute rejection. Transplantation 1987; 43: 8-12.
9. Demetris AJ, Nakamura K, Yagihashi A et al. A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology 1992; 16: 671-681.
10. Manez R, Kobayashi M, Takaya S et al. Humoral rejection associated with antidonor lymphocytotoxic antibodies following liver transplantation. Transplant Proc 1993; 25(1 Pt 2): 888-890. (Pubitemid 23078824)
11. Ratner LE, Phelan D, Brunt EM,Mohanakumar T, Hanto DW. Probable antibody-mediated failure of two sequential ABO-compatible hepatic allografts in a single recipient. Transplantation 1993; 55: 814-819. (Pubitemid 23122054)
12. Michaels PJ, Fishbein MC, Colvin RB. Humoral rejection of human organ transplants. Springer Semin Immunopathol 2003; 25: 119-140.
13. Colvin RB. C4d in liver allografts: A sign of antibody-mediated rejection? Am J Transplant 2006; 6: 447-448.
14. Castillo-Rama M, Castro MJ, Bernardo I, et al. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: Role of human leukocyte antigen compatibility. Liver Transpl 2008; 14: 554-562. (Pubitemid 351524413)
15. Goh A, Scalamogna M, De Feo T, Poli F, Terasaki PI. Human leukocyte antigen crossmatch testing is important for liver retransplantation. Liver Transpl 2010; 16: 308-313.
16. Takaya S, Duquesnoy R, Iwaki Y et al. Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. Transplant Proc 1991; 23(1 Pt 1): 396-399.
17. Demetris AJ, Murase N, Nakamura K et al. Immunopathology of antibodies as effectors of orthotopic liver allograft rejection. Semin Liver Dis 1992; 12: 51-59.
18. Feucht HE. Complement C4d in graft capillaries: The missing link in the recognition of humoral alloreactivity. Am J Transplant 2003; 3: 646-652. (Pubitemid 36745236)
19. Schmeding M, Dankof A, Krenn V et al. C4d in acute rejection after liver transplantation: A valuable tool in differential diagnosis to hepatitis C recurrence. Am J Transplant 2006; 6: 523-530. (Pubitemid 43382138)
20. Sakashita H, Haga H, Ashihara E et al. Significance of C4d staining in ABO-identical/compatible liver transplantation. Mod Pathol 2007; 20: 676-684. (Pubitemid 46788874)
21. Watson R, Kozlowski T, Nickeleit V et al. Isolated donor specific alloantibody-mediated rejection after ABO compatible liver transplantation. Am J Transplant 2006; 6: 3022-3029.
22. Schadde E, d'Alessandro AM, Musat AI, Torrealba JR, Knechtle SJ. Donor-specific HLA-antibody-mediated humoral rejection in a liver transplant recipient fully reversed with plasmapheresis and immunoglobulin. Clin Transpl 2006: 479-482.
23. Wilson CH, Agarwal K, Carter V et al. Late humoral rejection in a compliant ABO-compatible liver transplant recipient. Transplantation 2006; 82: 988-989. (Pubitemid 44564051)
24. Hadaya K, Ferrari-Lacraz S, Giostra E et al. Humoral and cellular rejection after combined liver-kidney transplantation in low immunologic risk recipients. Transpl Int 2009; 22: 242-246.
25. Kamar N, Lavayssiere L,Muscari F et al. Early plasmapheresis and rituximab for acute humoral rejection after ABO-compatible liver transplantation. World J Gastroenterol 2009; 15: 3426-3430.
26. Roskams T, Desmet V. Ductular reaction and its diagnostic significance. Semin Diagn Pathol 1998; 15: 259-269. (Pubitemid 28536759)
27. Lachmann N, Terasaki PI, Budde K et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex post-transplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87: 1505-1513.
28. Seemayer CA, Gaspert A,Nickeleit V, Mihatsch MJ. C4d staining of renal allograft biopsies: A comparative analysis of different staining techniques. Nephrol Dial Transplant 2007; 22: 568-576. (Pubitemid 46189903)
29. Martelius T, Halme L, Arola J, Hockerstedt K, Lautenschlager I. Vascular deposition of complement C4d is increased in liver allografts with chronic rejection. Transpl Immunol 2009; 21: 244-246.
30. Moeller J, Krukemeyer MG, Morawietz L et al. Molecular case report: IgVH analysis in acute humoral and cellular liver allograft rejection suggests a selected accumulation of effector B cells and plasma cells. Virchows Arch 2005; 446: 325-332. (Pubitemid 40558391)
31. Hori T, Uemoto S, Takada Y et al. Does a positive lymphocyte cross-match contraindicate living-donor liver transplantation? Surgery 2010; 147: 840-844.
32. Dankof A, Schmeding M, Morawietz L et al. Portal capillary C4d deposits and increased infiltration by macrophages indicate humorally mediated mechanisms in acute cellular liver allograft rejection. Virchows Arch 2005; 447: 87-93. (Pubitemid 41126244)
33. Solez K, Colvin RB, Racusen LC et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753-760. (Pubitemid 351347767)
34. de Kort H, Munivenkatappa RB, Berger SP et al. Pancreas allograft biopsies with positive C4d staining and anti-donor antibodies related to worse outcome for patients. Am J Transplant 2010; 10: 1660-1667.
35. Bu X, Zheng Z, Yu Y, Zeng L, Jiang Y. Significance of C4d deposition in the diagnosis of rejection after liver transplantation. Transplant Proc 2006; 38: 1418-1421.
36. Alvarez-Marquez A, Aguilera I, Gentil MA et al. Donor-specific antibodies against HLA, MICA, and GSTT1 in patients with allograft rejection and C4d deposition in renal biopsies. Transplantation 2009; 87: 94-99.
37. Fujita T, Matsushita M, Endo Y. The lectin-complement pathway: Its role in innate immunity and evolution. Immunol Rev 2004; 198: 185-202. (Pubitemid 38406944)
38. Mold C, Gewurz H, Du Clos TW. Regulation of complement activation by C-reactive protein. Immunopharmacology 1999; 42: 23-30. (Pubitemid 29322284)
39. Bouron-Dal Soglio D, Rougemont AL, Herzog D, Soucy G, Alvarez F, Fournet JC. An immunohistochemical evaluation of C4d deposition in pediatric inflammatory liver diseases. Hum Pathol 2008; 39: 1103-1110. (Pubitemid 351822384)
40. Rensen SS, Slaats Y, Driessen A et al. Activation of the complement system in human nonalcoholic fatty liver disease. Hepatology 2009; 50: 1809-1817.
41. Steinhoff G, Wonigeit K, Pichlmayr R. Analysis of sequential changes in major histocompatibility complex expression in human liver grafts after transplantation. Transplantation 1988; 45: 394-401. (Pubitemid 18084683)
42. Hubscher SG, Adams DH, Elias E. Changes in the expression of major histocompatibility complex class II antigens in liver allograft rejection. J Pathol 1990; 162: 165-171. (Pubitemid 20336828)
43. Batts KP, Moore SB, Perkins JD, Wiesner RH, Grambsch PM, Krom RA. Influence of positive lymphocyte crossmatch and HLA mismatching on vanishing bile duct syndrome in human liver allografts. Transplantation 1988; 45: 376-379. (Pubitemid 18084679)
44. Donaldson PT, Alexander GJ, O'Grady J et al. Evidence for an immune response to HLA class I antigens in the vanishing-bileduct syndrome after liver transplantation. Lancet 1987; 1: 945-951.
45. Troxell ML, Higgins JP, Kambham N. Evaluation of C4d staining in liver and small intestine allografts. Arch Pathol Lab Med 2006; 130: 1489-1496. (Pubitemid 44520715)
46. Lorho R, Turlin B, Aqodad N et al. C4d: A marker for hepatic transplant rejection. Transplant Proc 2006; 38: 2333-2334. (Pubitemid 46068533)
47. Ludwig J, Wiesner RH, Batts KP, Perkins JD, Krom RA. The acute vanishing bile duct syndrome (acute irreversible rejection) after orthotopic liver transplantation. Hepatology 1987; 7: 476-483. (Pubitemid 17073152)
48. Matsumoto Y, McCaughan GW, Bishop GA. Portal capillary destruction in liver allograft rejection. Transplant Proc 1992; 24: 196-197.
49. Takemura M, Oguma S,Mori S et al. Peribiliary vascular diseases in rejected livers: Computer-aided three-dimensional reconstruction and morphometry. Transplant Proc 1991; 23(1 Pt 2): 1409-1412.
50. Matsumoto Y,McCaughan GW, Painter DM, Bishop GA. Evidence that portal tract microvascular destruction precedes bile duct loss in human liver allograft rejection. Transplantation 1993; 56: 69-75. (Pubitemid 23220574)
51. Heidt S, Roelen DL, Eijsink C et al. Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. Clin Exp Immunol 2010; 159: 199-207.
52. Cruzado JM, Bestard O, Grinyo JM. Control of anti-donor antibody production post-transplantation: Conventional and novel immunosuppressive therapies. Contrib Nephrol 2009; 162: 117-128.
53. Krukemeyer MG, Moeller J, Morawietz L et al. Description of B lymphocytes and plasma cells, complement, and chemokines/receptors in acute liver allograft rejection. Transplantation 2004; 78: 65-70.
54. Rostron A, Carter V,MutungaMet al. A case of acute humoral rejection in liver transplantation: Successful treatment with plasmapheresis and mycophenolate mofetil. Transpl Int 2005; 18: 1298-1301.
55. Sawada T, Shimizu A, Kubota K, Fuchinoue S, Teraoka S. Lobular damage caused by cellular and humoral immunity in liver allograft rejection. Clin Transplant 2005; 19: 110-114. (Pubitemid 40227861)
56. Jain A, Ryan C, Mohanka R et al. Characterization of CD4, CD8, CD56 positive lymphocytes and C4d deposits to distinguish acute cellular rejection from recurrent hepatitis C in post-liver transplant biopsies. Clin Transplant 2006; 20: 624-633. (Pubitemid 44383409)
57. Bellamy CO, Herriot MM, Harrison DJ, Bathgate AJ. C4d immunopositivity is uncommon in ABO-compatible liver allografts, but correlates partially with lymphocytotoxic antibody status. Histopathology 2007; 50: 739-749. (Pubitemid 46683930)